C-C. Lin

671 citations

43 papers · 587 · h-index 10

Impact in

Hepatology top 5%
- Hepatitis C virus research
- Hepatocellular Carcinoma Treatment and Prognosis
Biotechnology top 10%
- Cancer Research and Treatments

Papers in

Pulmonary and Respiratory Medicine 15
- Lung Cancer Treatments and Mutations 10
- Prostate Cancer Treatment and Research 4
Oncology 15
- Cancer Immunotherapy and Biomarkers 5
- Colorectal Cancer Treatments and Studies 4
- HER2/EGFR in Cancer Research 3

Co-authors: Jin‐Shing Chen (2 shared papers)Lin Tm (1 shared paper)Chul‐Su Yang (1 shared paper)Chen Cj (1 shared paper)Yee Chao (1 shared paper)J. A. Thomson (1 shared paper)L-T. Chen (1 shared paper)JH Wang (1 shared paper)
Journals: Annals of Oncology (23 papers)British Journal of Cancer (3 papers)Cell Death Discovery (1 paper)Cell Death and Disease (1 paper)QJM (1 paper)
Partner nations: Taiwan United States South Korea

In The Last Decade

C-C. Lin

42 papers receiving 575 citations

Peers

Countries citing papers authored by C-C. Lin

Since Specialization

Citations

This map shows the geographic impact of C-C. Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C-C. Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C-C. Lin more than expected).

Fields of papers citing papers by C-C. Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C-C. Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C-C. Lin. The network helps show where C-C. Lin may publish in the future.

Co-authors

The 25 scholars most cited alongside C-C. Lin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with C-C. Lin Line = papers co-authored together C-C. Lin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 43 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Hepatitis B virus markers in Chinese twins. PubMed ·Lin Tm, Chen Cj, Wu Mm, Chul‐Su Yang, Jin‐Shing Chen, C-C. Lin, Kwang Ty, Hsu St, Lin Sy, LC Hsu	1989	150
2	A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients British Journal of Cancer ·TS Yang, SN Lu, Yee Chao, I.-Shyan Sheen, C-C. Lin, T. Wang, (unknown), JH Wang, L-Y Liao, J. A. Thomson, Jacqueline Wang-Peng, (unknown), L-T. Chen	2010	139
3	A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies British Journal of Cancer ·C-C. Lin, Wu‐Chou Su, C-J. Yen, Chih‐Hung Hsu, W-P Su, (unknown), Yen‐Shen Lu, (unknown), Deng-Gao Huang, Holger Fritsch, (unknown), Tillmann Taube, James Chih‐Hsin Yang	2014	66
4	Interconnections between autophagy and the coagulation cascade in hepatocellular carcinoma Cell Death and Disease ·K-D Chen, (unknown), M-C Tsai, C-H Wu, H-J Yang, L-Y Chen, Toshiaki Nakano, Shigeru Goto, K-T Huang, T-H Hu, (unknown), C-C. Lin	2014	31
5	Basal core promoter mutation is associated with progression to cirrhosis rather than hepatocellular carcinoma in chronic hepatitis B virus infection British Journal of Cancer ·(unknown), C-C. Lin, Yee‐Chun Chen, (unknown), S-M Lin, Y‐F Liaw	2012	28
6	Risk of tumour progression in early-stage hepatocellular carcinoma after radiofrequency ablation British journal of surgery ·Maria da Luz Fernandes, C-C. Lin, C-J Lin, W-T Chen, S-M Lin	2009	18
7	(Nucleic Acids Res., 34:W571-W577)CRSD: a comprehensive web server for composite regulatory signature discovery Liu Cc, C-C. Lin, Chen Wse, Chen Hy, Chang Pc, Chen Jjw, Yang Pc	2006	18
8	Factor VII promotes hepatocellular carcinoma progression through ERK-TSC signaling Cell Death Discovery ·M-C Tsai, K-D Chen, (unknown), K-T Huang, C-H Wu, I.-Ying Kuo, L-Y Chen, T-H Hu, Shigeru Goto, Toshiaki Nakano, Anthony Dorling, John H. McVey, (unknown), C-C. Lin	2015	17
9	The potential impact of sleep-related movement disorders on stroke risk: a population-based longitudinal study QJM ·C-H Chou, J-H Yin, (unknown), C-C. Lin, Y-F Sung, C-H Chung, W-C Chien, (unknown), (unknown), G-Y Lin, (unknown), J.-T. Lee	2017	11
10	1256MO Phase I/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours Annals of Oncology ·B. Besse, Alexander Drilon, BC Cho, D. Ross Camidge, Joel W. Neal, C-C. Lin, S.V. Liu, M. Nagasaka, S.C-H. Kao, Eudald Felip, Anthonie J. van der Wekken, C.-C. Lin, J.R. Bauman, S. Gadgeel, Manoj Samant, Jiayu Shen, Yun Sun, Viola W. Zhu, Vipul Upadhyay, W. Marston Linehan	2024	9
11	Radiofrequency ablation for hepatocellular carcinoma: use of lowvsmaximal radiofrequency power British Journal of Radiology ·Therese Capalongan Macatula, C-C. Lin, C-J Lin, W-T Chen, S-M Lin	2012	9
12	Impaired natural killer cytotoxicity during recrudescence of recurrent herpes simplex virus type 1 infection. PubMed ·Kuo Yc, Lin Cy, Cheng Sf, C-C. Lin, Liu Wt	1987	9
13	1765O Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC) Annals of Oncology ·William Kevin Kelly, Daniel C. Danila, C-C. Lin, Jia-Lin Lee, Nobuaki Matsubara, Patrick J. Ward, Andrew J. Armstrong, David Pook, M. Kim, Tanya B. Dorff, Stefanie Fischer, Y-C. Lin, Lisa G. Horvath, Christopher Sumey, Zhi Yang, Gabor Jurida, Jamie N. Connarn, Hugo A. Penny, Julia Stieglmaier, Leonard J. Appleman	2023	8
14	(Nucleic Acids Res., 34:4069-4080)Topology-based cancer classification and related pathway mining using microarray data Liu Cc, Chen Wse, C-C. Lin, Liu Hc, Chen Hy, Yang Pc, Chang Pc, Chen Jjw	2006	7
15	662MO Phase I, multi-center, dose-escalation and dose-expansion study of IMP7068, a WEE1 inhibitor, in patients with advanced solid tumors Annals of Oncology ·C-C. Lin, Jaspreet Singh Grewal, Joaquina Baranda, R.E. Schneider, Jian Zhang, L-Y. Bai, Y-M. Yeh, David Sommerhalder, Guang Li, Lin Shen, Hsu Hc, Olatunji B. Alese, Rutie Yin, C-Y. Hsieh, S.X. Cai, Ye Tian, Hao Xia, Binghao Li, Miao Zhang, Cheng Zhang	2023	6
16	561P Phase Ib study of ribociclib (R) + trametinib (T) in patients (pts) with metastatic/advanced solid tumours Annals of Oncology ·Patricia LoRusso, Marwan Fakih, Filip De Vos, J. Thaddeus Beck, Jaime R. Merchan, Geoffrey I. Shapiro, C-C. Lin, Jayesh Desai, Jennifer L. Spratlin, Teresa Cascella, Larissa Sandalic, Ahmed M. Abdelhady, Aislyn Boran, Eduard Gasal, Filip Jankú, Eric Van Cutsem	2020	5
17	1918P Final analysis of RIFTOS MKI, a global, non-interventional study assessing the use of multikinase inhibitors (MKIs) for the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC) Annals of Oncology ·Marcia S. Brose, Johannes W. A. Smit, C-C. Lin, Masayuki Tori, Daniel W. Bowles, Frank Worden, DER-CHUNG SHEN, S-M. Huang, Maria Alevizaki, Robin P. Peeters, Shunji Takahashi, P. O. Rumyantsev, Runquan Guan, Svetlana Babajanyan, Kirhan Özgürdal, Iwao Sugitani, Fabián Pitoia, Livia Lamartina	2020	5
18	Phase I/II study of S 49076, a MET/AXL/FGFR inhibitor, in combination with gefitinib in EGFR-mutated NSCLC patients who progress on EGFR tyrosine kinase inhibitor Annals of Oncology ·K. Park, Fortunato Ciardiello, Toyoaki Hida, Wan‐Teck Lim, C-C. Lin, Haruyasu Murakami, Makoto Nishio, F. Cantero, Valérie Cattan, Christine Gabarroca, E. Gandossi, Luis Paz‐Ares	2017	4
19	1287P Efficacy and safety of entrectinib in locally advanced/metastatic ROS1 fusion-positive NSCLC: An updated integrated analysis Annals of Oncology ·Matthew Krebs, Filippo de Braud, Salvatore Siena, Alexander Drilon, Robert C. Doebele, Manish R. Patel, Byoung Chul Cho, Stephen V. Liu, M-J. Ahn, C-H. Chiu, Anna F. Farago, C-C. Lin, Christos S. Karapetis, Yu‐Chuan Li, Fabrice Barlési, Brian Simmons, Bethany Pitcher, Rafał Dziadziuszko	2020	4
20	695P A phase I/Ib study evaluating the safety and tolerability of NIZ985 alone and in combination with spartalizumab (anti–PD-1) in patients (pts) with solid tumors or lymphoma Annals of Oncology ·Elena Garralda, A. Oberoi, Takafumi Koyama, P. Schoeffski, Paolo A. Ascierto, C-C. Lin, M.H.H. Schuler, Yan Xing, Sapna P. Patel, Vivek Subbiah, Nancy Lewis, J.B. Lee, Nadia B. Hassounah, L.H. Lee, Manas Kumar Roy, Susana Banerjee, Albert B. Reynolds, L. Wang Lakshman, Toshio Shimizu	2023	3

About C-C. Lin

C-C. Lin is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Immunology and Epidemiology, having authored 43 papers that have together received 587 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (10 papers), Cancer Immunotherapy and Biomarkers (5 papers), Colorectal Cancer Treatments and Studies (4 papers), Prostate Cancer Treatment and Research (4 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), HER2/EGFR in Cancer Research (3 papers), Thyroid Cancer Diagnosis and Treatment (3 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). The work is most often cited by research in Hepatology (130 citations), Biotechnology (95 citations), Epidemiology (182 citations), Cancer Research (77 citations) and Oncology (83 citations). C-C. Lin has collaborated with scholars based in Taiwan, United States and South Korea. Frequent co-authors include Jin‐Shing Chen, Lin Tm, Chul‐Su Yang, Chen Cj, Yee Chao, J. A. Thomson, L-T. Chen, JH Wang, TS Yang and Wu‐Chou Su. Their work appears in journals such as Annals of Oncology, British Journal of Cancer, Cell Death Discovery, Cell Death and Disease and QJM.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

C-C. Lin

Impact in

Papers in i

In The Last Decade

C-C. Lin

Peers

Countries citing papers authored by C-C. Lin

Fields of papers citing papers by C-C. Lin

All Works

About C-C. Lin

Explore authors with similar magnitude of impact

Papers in